Anteris Technologies has 3D single-piece Transcatheter Heart Valve DurAVR™ featured during TVT 2021
CEO Wayne Paterson said: “Having DurAVR™ recognized at this very important meeting is a clear demonstration of support for our potential within the Structural Heart Faculty.” DurAVR™ was also recognised by founder and chairman emeritus of the Cardiovascular Research Foundation.
Anteris Technologies Ltd (ASX:AVR, OTCQB:AMEUF, FRA:DDF) has had its unique 3D single-piece Transcatheter Heart Valve DurAVR™ featured in the innovation section of the Transcatheter Valve Therapies Structural Heart Summit (TVT 2021).
DurAVR™ was also recognised by the founder and chairman emeritus of the Cardiovascular Research Foundation (CRF), which sponsors TVT 2021.